Fibrolamellar carcinoma (FLC) is a rare and aggressive form of liver cancer that mostly occurs in young people and does not have any associated liver diseases such as cirrhosis or hepatitis. This pathological form is characterized by the formation of atypical cells with a fibrous stroma, which distinguishes it from the more common hepatocellular carcinomas. FLC is usually diagnosed at a late stage of the disease, which complicates treatment and reduces the chances of survival. Despite the fact that the disease is rare, its occurrence attracts the attention of researchers, which serves as a reason for further study of its etiology, pathogenesis, as well as effective methods of diagnosis and therapy.
History of the disease and interesting historical facts
Fibrolamellar carcinoma was first described in the scientific literature in 1956 by scientists from the United States, who drew attention to the morphological features of the neoplasm. Since then, this disease has become the subject of many clinical studies aimed at its understanding and diagnosis. Interestingly, in early publications, the disease was perceived as a type of liver adenoma, but subsequent studies revealed its true malignant nature. In medical practice, FLC remains the subject of intensive innovative research related to both molecular biology and genetics, as well as clinical aspects of treatment.
Epidemiology
Fibrolamellar carcinoma is relatively rare, accounting for less than 5% of all liver cancer cases. According to international statistics, this type of tumor is most often observed in people aged 15 to 40 years. Notably, patients with FLC do not have the genetic predisposition inherent in more common forms of hepatocellular carcinoma. Information on the incidence varies depending on the geographic region, but the highest rates are noted in countries with developed health care systems, where diagnostic capabilities allow the disease to be detected at an earlier stage.
Genetic predisposition to this disease
Modern molecular genetic studies have revealed the association of fibrolamellar carcinoma with several genes and mutations. The most important genes involved in the development of the disease are those responsible for the regulation of the cell cycle and apoptosis programs. In particular, loss of function of the CDKN2A and PRDM14 genes has been recorded, which can contribute to uncontrolled cell proliferation. However, it should be noted that to this day the main cause of FLC remains unclear, and all studies are ongoing, with the hope of identifying molecular targets for specific therapy.
Risk factors for the development of this disease
The risks of developing fibrolamellar carcinoma are associated with a number of factors, both physical and chemical, although the final causes of the disease have not yet been established. Among them are:
- Age – the greatest predisposition is observed in young people, from 15 to 40 years old;
- Gender – men are more susceptible to the disease;
- Chemical exposures – potential carcinogens such as aflatoxins, which may be present in certain foods;
- Presence of liver disease – although in most cases, FLC develops in patients without previous pathologies, there is still a connection with some forms of liver damage.
Diagnosis of this disease
The main diagnostics of fibrolamellar carcinoma is based on a comprehensive approach, including clinical manifestations, laboratory and radiological studies:
- The main symptoms include sudden weight loss, pain in the right hypochondrium, abdominal enlargement and severe weakness;
- Laboratory tests typically reveal elevated levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as increased bilirubin levels;
- Radiological examinations (ultrasound, CT and MRI) allow visualization of the tumor and assessment of its size;
- Other diagnostic tests, such as biopsy, are needed to definitively confirm the diagnosis;
- Differential diagnosis includes exclusion of other forms of hepatocellular carcinoma and metastatic liver lesions.
Treatment
The treatment strategy for fibrolamellar carcinoma depends on the stage of the disease and the general condition of the patient. General treatment involves a multidisciplinary approach that combines surgery, chemotherapy and radiotherapy:
- Pharmacological treatment may include drugs aimed at controlling tumor growth;
- Surgical treatment, in particular liver resection, is most effective in the early stages;
- Other treatments, such as locally ablative techniques, may be used for inoperable tumors.
List of medications used to treat this disease
Fibrolamellar carcinoma can be treated with a number of drugs:
- Sorefenib (Nexavar) is a tyrosine kinase inhibitor indicated for advanced liver cancer;
- Lapatinib and other similar agents directed at specific molecular targets;
- Immunotherapy is used in clinical trials.
Disease monitoring
Monitoring of fibrolamellar carcinoma includes regular follow-up examinations to assess the response to treatment and to detect possible recurrences. The prognosis of the disease depends on the stage at diagnosis and the aggressiveness of the tumor. Possible complications may include tumor recurrence, metastasis, and liver dysfunction.
Age-related features of the disease
Fibrolamellar carcinoma manifests differently in different age groups. Patients under 30 years of age may have a more aggressive course of the disease, while older people often have a more favorable prognosis. Particular attention should be paid to patients with concomitant liver disease.
Questions and Answers
- What are the main symptoms of fibrolamellar carcinoma? The main symptoms include sudden weight loss, pain in the right hypochondrium, abdominal enlargement and severe weakness.
- How is the disease diagnosed? Diagnosis of fibrolamellar carcinoma includes laboratory tests, radiological examinations and, if necessary, a biopsy of the tumor.
- What treatment is considered the most effective? The most effective treatment is surgery, including liver resection, especially in the early stages.
- What is the prognosis for fibrolamellar carcinoma? The prognosis depends on the stage of the disease; with early detection and treatment, the chances of survival increase significantly.
- Can fibrolamellar carcinoma be prevented? There are currently no clear recommendations for prevention, but avoiding carcinogens and regular screening may reduce the risk.
Dr. Oleg Korzhikov reminds that fibrolamellar carcinoma requires special attention already at the first symptoms. The doctor advises not to ignore chronic abdominal pain and, if possible, undergo regular medical examinations. It is also important to pay attention to changes in health, such as unexpected weight loss or fatigue. According to Dr. Korzhikov, "early diagnosis is the key to successful treatment, and requests for help at the first alarming symptoms can play a decisive role in the prognosis of treatment."
